Burkholderia cepacia is an opportunistic nosocomial pathogen causing infections in immunocompromised hosts. Infection by Burkholderia in an immunocompetent host is a rare entity. We report a case of dengue and scrub coinfection complicated by B. cepacia bloodstream infection along with literature review of such infections in immunocompetent adults. Before the introduction of automated technologies, it was difficult to differentiate this organism from other aerobic Gram-negative nonfermenters, which have different intrinsic resistance profiles. Furthermore, Burkholderia has intrinsic as well as acquired resistance to various antimicrobials but not commonly to ceftazidime. To our knowledge, ours is the first case of multidrug-resistant B. cepacia infection in an immunocompetent host to be reported till date.
INTRODUCTION
Burkholderia cepacia is a rare opportunistic nosocomial pathogen causing infections in immunocompromised hosts such as those having cystic fibrosis, chronic granulomatous disease, hematological malignancies, chronic renal failure, and uncontrolled diabetes mellitus. In these patients, cepacia syndrome may present with fever, leukocytosis, pulmonary infiltrates, respiratory distress (necrotizing pneumonia), and septicemia. B. cepacia is one of the four notorious aerobic lactose nonfermenting, catalase-positive, oxidase-positive Gram-negative bacilli. [1] Here, we presented a case of B. cepacia bacteremia first of its kind, which is multidrug resistant (MDR) in a young immunocompetent patient having dengue and scrub typhus coinfection and reviewed the literature of B. cepacia infection in immunocompetent adult patients.
CASE REPORT
A 25-year-old male with no previous comorbidities was admitted in a hospital with a history of high-grade fever for 6 days, diffuse abdominal pain for 2 days, and one episode of hematemesis. Laboratory workup revealed anemia ,thrombocytopenia, hyperbilirubinemia with raised transaminases ,normal coagulation profile and renal function (hemoglobin 10 g/dl, total leukocyte count 5300/cumm, platelet count 15,000/cumm, serum creatinine 1.0 mg/dl, bilirubin (total/direct) 1.9/1.0 mg/dl, SGOT/SGPT/ALP3390/1150/93 IU/L, INR 1.0) dengue NS1 antigen positive, malaria antigen and smear negative, chest radiograph, and computed tomography (CT) scan [ Figure 1a ] showed dense bilateral lower lobe consolidation. In the next 2 days, he developed
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For reprints contact: reprints@medknow.com acute respiratory distress syndrome (ARDS) requiring intubation and mechanical ventilation and septic shock, for which broad-spectrum antimicrobials (meropenem and doxycycline) were started, and he was referred to Intensive Care Unit (ICU) of our institute for further management. At the time of admission in ICU, he had fever (core temp 40°C), heart rate of 130/min, blood pressure (invasive) 130/70 mmHg on norepinephrine infusion (0.1 µg/kg/ min), sedated with midazolam (3 mg/h) and fentanyl (100 µg/h), and on mechanical ventilation (PC/PEEP: 20/10 cm H 2 O, respiratory rate 30/min, FiO 2 :0.8). ICU severity scores were as follows: APACHE II 20 and SOFA 12. Initial laboratory workup at admission showed improving thrombocytopenia and liver function tests. Workup for tropical infections revealed positive dengue IgM and positive scrub typhus serology. Procalcitonin was elevated at 6.5 ng/ml. Due to severe ARDS (PaO 2 /FiO 2 ratio 100), he was proned for 12 h, after which his oxygenation status improved (PaO 2 /FiO 2 ratio 220). Broad-spectrum antimicrobials were continued. However, he had persistent high-grade fever (core temperature 40°C) for the next 3 days despite recovering from septic shock. Three blood cultures drawn at admission grew B. cepacia which was resistant to amikacin (MIC >32), aztreonam (MIC >16), ceftazidime (MIC >16), and cefoperazone-sulbactam (MIC 16:64) and sensitive to levofloxacin (MIC: 2), meropenem (MIC: 2), and trimethoprim-sulfamethoxazole (MIC <0.5/9). Furthermore, endotracheal aspirates at ICU admission revealed the growth of methicillin-resistant Staphylococcus aureus (sensitive to linezolid and vancomycin). Antimicrobials were changed to doripenem, linezolid, and cotrimoxazole. Over 24-36 h following change of antimicrobials, fever reduced in intensity, which was followed by successful extubation 48 h later. Repeat blood cultures after 1 week of therapy with cotrimoxazole were sterile. Procalcitonin decreased to 0.5 ng/ml. CT imaging at discharge showed cavitatory lesions with bronchiectatic changes in the lungs [ Figure 1b ] which resolved after few days.
DISCUSSION
This is the first reported case of MDR B. cepacia bacteremia to our knowledge, in an immunocompetent host. The patient might have acquired infection during his earlier hospital stay. We verified that there was no epidemic of such infections in both the hospitals.
In the largest series (95 patients) of B. cepacia bacteremia from Taiwan, Liao et al. reported that 96% patients had more than one underlying disease. After personal communication with the corresponding author, we did not receive any information as to whether there was any immunocompetent patient in their cohort. [2] In literature review, we found only nine case reports of B. cepacia in immunocompetent adult patients (age 25-66 years; male/female 7/1) as cited in Table 1 . Sites of infection predominantly were lungs in five cases, [3, 5, 7, 9] with one each in synovial fluid, [4] urachal abscess, [6] and one in blood causing native valve endocarditis. [8] In our case, it was in bloodstream infection.
B. cepacia, also labeled as "B. cepacia complex (BCC)" or nonmeliod Burkholderia species, [1] was previously mislabeled as Pseudomonas cepacia before the availability of automated technologies such as matrix-assisted laser desorption ionization, and time-of-flight mass spectrometry/Phoenix/Vitek-2/WalkAway systems. This is of great concern to the clinician as therapy differs for these organisms, which may lead to poor outcome. BCC is intrinsically resistant to first-and second-generation cephalosporins, aminoglycosides, antipseudomonal [4] 58/female Septic arthritis Synovial fluid Gentamycin Survived Waterer et al., 1999 [5] 32/male CAP Lungs Quinolone Survived Hsu et al., 2005 [6] 56/male Acute omphalitis with urachal abscess Urachal abscess Amoxicillin/clavulanic acid Survived
Bayram et al., 2011 [7] 60/male CAP Lungs Ciprofloxacin Survived Bayram et al., 2011 [7] 66/male CAP Lungs Levofloxacin Survived Ki et al., 2011 [8] 77/female Spinal compression fracture with stroke and mitral stenosis (native valve endocarditis) Blood Ceftazidime Survived
Karanth et al., 2012 [9] 32 penicillins, and polymyxins due to altered outer membrane permeability barrier (OMP) and efflux pumps. [10] Acquired resistance is through production of beta-lactamases and modifying enzymes other than beta-lactamases. Usual treatment regimens include ceftazidime, minocycline, meropenem, or cotrimoxazole. Majority of BCC are susceptible to ceftazidime, [2] but the BCC isolated in our case was resistant to this agent with high MIC (>16) which required administration of cotrimoxazole. Our case highlights that B. cepacia may complicate community-acquired infections even in immunocompetent patients.
CONCLUSION
B. cepacia, a microorganism causing infections in immunocompromised hosts, can complicate community-acquired infections as seen in our patient who is immunocompetent host. This organism historically described with low virulence can cause life-threatening infections. Proper identification of this organism and antibiotic susceptibility testing with the help of available automated technologies along with timely treatment with antimicrobials forms the key to management, due to varied resistance patterns noted.
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